Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells

Leukemia

Volumn 25, Issue 6, 2011, Pages 1053-1056

  Stamova, S ^a   Cartellieri, M ^a   Feldmann, A ^a   Bippes, C C ^a   Bartsch, H ^a   Wehner, R ^a   Schmitz, M ^a   Von Bonin, M ^b   Bornhauser M ^b   Ehninger, G ^b   Rieber, E P ^a   Bachmann, M ^a,c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY CD 33; CD3 ANTIGEN; CD33 ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL SURFACE; CYTOKINE RELEASE; DRUG PROTEIN BINDING; EFFECTOR CELL; HUMAN; LEUKAPHERESIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K;

EID: 79958150186     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.42     Document Type: Article

References (8)

1. O'Reilly MK, Paulson JC. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci 2009; 30: 240-248.
2. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490-1496. (Pubitemid 32708610)
3. Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F et al. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 2010; 33: 599-608.
4. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009; 11: 22-30.
5. von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S et al. A novel bispecific protein (ULBP2- BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107: 1955-1962. (Pubitemid 43289377)
6. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255-260. (Pubitemid 33706003)
7. Maccalli C, Scaramuzza S, Parmiani G. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors. Cancer Immunol Immunother 2009; 58: 801-808.
8. Carmo-Fonseca M, Pfeifer K, Schroder HC, Vaz MF, Fonseca JE, Muller WE et al. Identification of La ribonucleoproteins as a component of interchromatin granules. Exp Cell Res 1989; 185: 73-85. (Pubitemid 19284956)